CXCR4 mRNA overexpression in high grade prostate tumors: Lack of association with TMPRSS2-ERG rearrangement

Cancer Biomarkers

Volumn 12, Issue 1, 2012, Pages 21-30

  De Muga, Silvia ^a,c   Hernández, Silvia ^b   Salido, Marta ^a   Lorenzo, Marta ^a   Agell, Laia ^a   Juanpere, Núria ^a   Lorente, José A ^a,c   Serrano, Sergio ^a,c   Lloreta, Josep ^a,b  

^a HOSPITAL DEL MAR   (Spain)

^b UNIVERSITAT POMPEU FABRA   (Spain)

^c UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

Author keywords

CXCR4; ERG; Overexpression; Prostate cancer; Rearrangement; TMPRSS2

Indexed keywords

CHEMOKINE RECEPTOR CXCR4; HYBRID PROTEIN; MESSENGER RNA; TMPRSS2 ERG FUSION PROTEIN; TRANSCRIPTION FACTOR ERG; UNCLASSIFIED DRUG;

ARTICLE; CANCER DIAGNOSIS; CANCER PATIENT; CANCER PROGNOSIS; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE SEVERITY; FLUORESCENCE IN SITU HYBRIDIZATION; GENE EXPRESSION; GENE OVEREXPRESSION; GENE REARRANGEMENT; GENETIC ASSOCIATION; GLEASON SCORE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; PREDICTIVE VALUE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY;

GENE EXPRESSION REGULATION, NEOPLASTIC; GENE REARRANGEMENT; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; MALE; NEOPLASM GRADING; ONCOGENE PROTEINS, FUSION; PROSTATIC NEOPLASMS; RECEPTORS, CXCR4; RNA, MESSENGER; TRANS-ACTIVATORS;

EID: 84872833906     PISSN: 15740153     EISSN: 18758592     Source Type: Journal    
DOI: 10.3233/CBM-2012-00288     Document Type: Article

References (46)

1. Tomlins SA, Rhodes DR, Perner S, et al. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 310 (2005) 644-648. (Pubitemid 41528150)
2. Albadine R, Latour M, Toubaji A, et al. TMPRSS2-ERG gene fusion status in minute (minimal) prostatic adenocarcinoma. Mod Pathol 22 (2009) 1415-1422.
3. Esgueva R, Perner S, LaFargue J, et al. Prevalence of TMPRSS2-ERG and SLC45A3-ERG gene fusions in a large prostatectomy cohort. Mod Pathol 23 (2010) 539-546.
4. Gopalan A, Leversha MA, Satagopan JM, et al. TMPRSS2-ERG gene fusion is not associated with outcome in patients treated by prostatectomy. Cancer Res 69 (2009) 1400-1406.
5. Mehra R, Tomlins SA, Shen R, et al. Comprehensive assessment of TMPRSS2 and ETS family gene aberrations in clinically localized prostate cancer. Mod Pathol 20 (2007) 538-544. (Pubitemid 46631996)
6. Mosquera JM, Mehra R, Regan MM, et al. Prevalence of TMPRSS2-ERG fusion prostate cancer among men undergoing prostate biopsy in the United States. Clin Cancer Res 15 (2009) 4706-4711.
7. Perner S, Demichelis F, Beroukhim R, et al. TMPRSS2: ERG fusion-associated deletions provide insight into the heterogeneity of prostate cancer. Cancer Res 66 (2006) 8337-8341. (Pubitemid 44449140)
8. Soller MJ, Isaksson M, Elfving P, et al. Confirmation of the high frequency of the TMPRSS2/ERG fusion gene in prostate cancer. Genes Chromosomes Cancer 45 (2006) 717-719. (Pubitemid 43727158)
9. Svensson MA, LaFargue CJ, MacDonald TY, et al. Testing mutual exclusivity of ETS rearranged prostate cancer. Lab Invest 91 (2011) 404-412.
10. Tu JJ, Rohan S, Kao J, et al. Gene fusions between TMPRSS2 and ETS family genes in prostate cancer: frequency and transcript variant analysis by RT-PCR and FISH on paraffin-embedded tissues. Mod Pathol 20 (2007) 921-928. (Pubitemid 47267823)
11. Winnes M, Lissbrant E, Damber JE, Stenman G. Molecular genetic analyses of the TMPRSS2-ERGand TMPRSS2-ETV1 gene fusions in 50 cases of prostate cancer. Oncol Rep 17 (2007) 1033-1036.
12. Yoshimoto M, Joshua AM, Cunha IW, et al. Absence of TMPRSS2: ERG fusions and PTEN losses in prostate cancer is associated with a favorable outcome. Mod Pathol 21 (2008) 1451-1460.
13. Tomlins SA, Mehra R, Rhodes DR, et al. TMPRSS2: ETV4 gene fusions define a third molecular subtype of prostate cancer. Cancer Res 66 (2006) 3396-3400.
14. Helgeson BE, Tomlins SA, Shah N, et al. Characterization of TMPRSS2: ETV5 and SLC45A3: ETV5 gene fusions in prostate cancer. Cancer Res 68 (2008) 73-80. (Pubitemid 351380107)
15. Han B, Mehra R, Suleman K, et al. Characterization of ETS gene aberrations in select histologic variants of prostate carcinoma. Mod Pathol 22 (2009) 1176-1185.
16. Hermans KG, Bressers AA, van der Korput HA, et al. Two unique novel prostate-specific and androgen-regulated fusion partners of ETV4 in prostate cancer. Cancer Res 68 (2008) 3094-3098.
17. Tomlins SA, Laxman B, Dhanasekaran SM, et al. Distinct classes of chromosomal rearrangements create oncogenic ETS gene fusions in prostate cancer. Nature 448 (2007) 595-599. (Pubitemid 47206938)
18. Attard G, Clark J, Ambroisine L, et al. Duplication of the fusion of TMPRSS2 to ERG sequences identifies fatal human prostate cancer. Oncogene 27 (2008) 253-263.
19. Demichelis F, Fall K, Perner S, et al. TMPRSS2:ERG gene fusion associated with lethal prostate cancer in a watchful waiting cohort. Oncogene 26 (2007) 4596-4599. (Pubitemid 47037039)
20. Nam RK, Sugar L, Wang Z, et al. Expression of TMPRSS2: ERG gene fusion in prostate cancer cells is an important prognostic factor for cancer progression. Cancer Biol Ther 6 (2007) 40-45. (Pubitemid 46294173)
21. Petrovics G, Liu A, Shaheduzzaman S, et al. Frequent overexpression of ETS-related gene-1 (ERG1) in prostate cancer transcriptome. Oncogene 24 (2005) 3847-3852. (Pubitemid 40826884)
22. Demichelis F, RubinMA. TMPRSS2-ETS fusion prostate cancer: biological and clinical implications. J Clin Pathol 60 (2007) 1185-1186. (Pubitemid 350084536)
23. Tomlins SA, Laxman B, Varambally S, et al. Role of the TMPRSS2-ERG gene fusion in prostate cancer. Neoplasia 10 (2008) 177-188. (Pubitemid 351240884)
24. Carver BS, Tran J, Gopalan A, et al. Aberrant ERG expression cooperates with loss of PTEN to promote cancer progression in the prostate. Nat Genet 41 (2009) 619-624.
25. Park K, Tomlins SA, Mudaliar KM, et al. Antibody-based detection of ERG rearrangement-positive prostate cancer. Neoplasia 12 (2010) 590-598.
26. Tomlins SA, Bjartell A, Chinnaiyan AM, et al. ETS gene fusions in prostate cancer: From discovery to daily clinical practice. Eur Urol 56 (2009) 275-286.
27. Cai J, Kandagatla P, Singareddy R, et al. Androgens Induce Functional CXCR4 through ERG Factor Expression in TMPRSS2-ERGFusion-Positive Prostate Cancer Cells. Transl Oncol 3 (2010) 195-203.
28. Furusato B, Mohamed A, Uhlen M, Rhim JS. CXCR4 and cancer. Pathol Int 60 (2010) 497-505.
29. Akashi T, Koizumi K, Tsuneyama K, et al. Chemokine receptor CXCR4 expression and prognosis in patientswithmetastatic prostate cancer. Cancer Sci 99 (2008) 539-542. (Pubitemid 351228571)
30. Arya M, Patel HR, McGurk C, et al. The importance of the CXCL12-CXCR4 chemokine ligand-receptor interaction in prostate cancer metastasis. J Exp Ther Oncol 4 (2004) 291-303. (Pubitemid 40189442)
31. Gladson CL,Welch DR. New insights into the role of CXCR4 in prostate cancer metastasis. Cancer Biol Ther 7 (2008) 1849-1851.
32. Hart CA, Brown M, Bagley S, Sharrard M, Clarke NW. Invasive characteristics of human prostatic epithelial cells: Understanding the metastatic process. Br J Cancer 92 (2005) 503-512. (Pubitemid 40395531)
33. Ratajczak MZ, Zuba-Surma E, KuciaM, et al. The pleiotropic effects of the SDF-1-CXCR4 axis in organogenesis, regeneration and tumorigenesis. Leukemia 20 (2006) 1915-1924. (Pubitemid 44614878)
34. Singh S, Singh UP, Grizzle WE, Lillard JW, Jr. CXCL12-CXCR4 interactions modulate prostate cancer cell migration, metalloproteinase expression and invasion. Lab Invest 84 (2004) 1666-1676. (Pubitemid 39600573)
35. Taichman RS, Cooper C, Keller ET, et al. Use of the stromal cell-derived factor-1/CXCR4 pathway in prostate cancer metastasis to bone. Cancer Res 62 (2002) 1832-1837. (Pubitemid 34408510)
36. de Muga S, Hernandez S, Agell L, et al. Molecular alterations of EGFR and PTEN in prostate cancer: association with highgrade and advanced-stage carcinomas. Mod Pathol 23 (2010) 703-712.
37. Agell L,Hernandez S, SalidoM, et al. PI3K signaling pathway is activated by PIK3CA mRNA overexpression and copy gain in prostate tumors, but PIK3CA, BRAF, KRAS and AKT1 mutations are infrequent events. Mod Pathol 24 (2011) 443-452.
38. Scheble VJ, Braun M, Beroukhim R, et al. ERG rearrangement is specific to prostate cancer and does not occur in any other common tumor. Mod Pathol 23 (2010) 1061-1067.
39. Tomlins SA, Aubin SM, Siddiqui J, et al. Urine TMPRSS2-ERG fusion transcript stratifies prostate cancer risk in men with elevated serum PSA. Sci Transl Med 3 (2011) 94ra72.
40. King JC,Xu J,Wongvipat J, et al. Cooperativity of TMPRSS2-ERG with PI3-kinase pathway activation in prostate oncogenesis. Nat Genet 41 (2009) 524-526.
41. Falzarano SM, Zhou M, Carver P, et al. ERG gene rearrangement status in prostate cancer detected by immune his to chemistry. Virchows Arch (2011).
42. Mochizuki H, Matsubara A, Teishima J, et al. Interaction of ligand-receptor system between stromal-cell-derived factor-1 and CXC chemokine receptor 4 in human prostate cancer: A possible predictor of metastasis. Biochem Biophys Res Commun 320 (2004) 656-663. (Pubitemid 38887194)
43. Sun YX, Wang J, Shelburne CE, et al. Expression of CXCR4 and CXCL12 (SDF-1) in human prostate cancers (PCa) in vivo. J Cell Biochem 89 (2003) 462-473. (Pubitemid 36648768)
44. Jung SJ, Kim CI, Park CH, et al. Correlation between Chemokine Receptor CXCR4 expression and prognostic factors in patients with prostate cancer. Korean J Urol 52 (2011) 607-611.
45. Dhanasekaran SM, Barrette TR, GhoshD, et al. Delineation of prognostic biomarkers in prostate cancer. Nature 412 (2001) 822-826. (Pubitemid 32801464)
46. Lapointe J, Kim YH, Miller MA, et al. A variant TMPRSS2 isoform and ERG fusion product in prostate cancer with implications for molecular diagnosis.Mod Pathol 20 (2007) 467-473. (Pubitemid 46482370)